-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
-
Modern Brain Radiotherapy in SCLC: Integrating Hippocampal Avoidance and Stereotactic Precision
Drs. Tomasik and Dziadziuszko discuss how the SCLC field is shifting toward brain-sparing techniques to maximize disease control, as well as cognitive preservation.
-
A Comprehensive Framework: Integrating Smoking Cessation into LCS
Experts outline how Poland aims to reduce lung cancer mortality while addressing one of the nation’s most persistent health challenges: tobacco dependence.
-
The Importance of Compassion and Clear Communication: A Patient Advocate Perspective
Patient advocate Kate Sinclair shares why communication is one of the most important tools for improving the patient experience during their lung cancer journey.
-
In Brief for January 14, 2026
The US FDA grants special designation to risvutatug rezetecan for SCLC and approves the subcutaneous formulation of amivantamab plus hyaluronidase-lpuj for EGFR+ NSCLC.